Puma Biotechnology (PBYI) director sells shares and receives 27,000 RSUs

Rhea-AI Filing Summary

Puma Biotechnology director Troy Edward Wilson reported both a stock grant and a sale of shares of common stock. He received 27,000 Restricted Stock Units (RSUs) that vest in full on the earlier of one year from grant or the next annual shareholder meeting, subject to his continued service with the company.

Wilson also completed an open-market sale of 10,800 shares at a weighted average price of $7.1989 per share under a pre-arranged Rule 10b5-1(c) trading plan adopted on 03-12-2025. Following these transactions, he holds 59,750 shares directly, plus 550 shares indirectly through accounts for two children.

Insider Trade Summary 10b5-1

Net Seller: 10,800 shares ($77,748)

Net Sell 4 txns

Insider WILSON TROY EDWARD

Role null

Sold 10,800 shs ($78K)

Type	Security	Shares	Price	Value
Sale	Common Stock	10,800	$7.1989	$78K
Grant/Award	Common Stock	27,000	$0.00	--
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 59,750 shares (Direct, null); Common Stock — 400 shares (Indirect, By Child #1)

Footnotes (1)

1. Represents Restricted Stock Units which vest in full on the earlier of the one-year anniversary of the date of grant and the date of the annual shareholder meeting following the date of grant, subject to the Reporting Person's continued service with the Issuer. Adoption date of referenced 10b5-1(c) plan is: 03-12-2025 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.98 to $7.32, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

Key Figures

Shares sold: 10,800 shares Sale price (weighted average): $7.1989 per share Sale price range: $6.98–$7.32 per share +4 more

7 metrics

Shares sold 10,800 shares Open-market sale of common stock

Sale price (weighted average) $7.1989 per share Weighted average sale price for 10,800 shares

Sale price range $6.98–$7.32 per share Price range of multiple sale transactions

RSUs granted 27,000 units Restricted Stock Units awarded to director

Direct holdings after transactions 59,750 shares Common stock held directly by Wilson post-transaction

Indirect holdings (children) 550 shares 400 shares for Child #1, 150 shares for Child #2

10b5-1 plan adoption date 03-12-2025 Adoption date of the Rule 10b5-1(c) trading plan

Key Terms

Restricted Stock Units, Rule 10b5-1(c) plan, weighted average price

3 terms

Restricted Stock Units financial

"Represents Restricted Stock Units which vest in full on the earlier of the one-year anniversary of the date of grant..."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Rule 10b5-1(c) plan regulatory

"Adoption date of referenced 10b5-1(c) plan is: 03-12-2025"

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

WILSON TROY EDWARD

(Last) (First) (Middle)

C/O PUMA BIOTECHNOLOGY, INC.

10880 WILSHIRE BOULEVARD, SUITE 1700

(Street)

LOS ANGELES CALIFORNIA 90024

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
PUMA BIOTECHNOLOGY, INC. [ PBYI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/11/2026		A		27,000	A	$0(1)	70,550	D
Common Stock	06/12/2026		S(2)		10,800	D	$7.1989(3)	59,750	D
Common Stock								400	I	By Child #1
Common Stock								150	I	By Child #2

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents Restricted Stock Units which vest in full on the earlier of the one-year anniversary of the date of grant and the date of the annual shareholder meeting following the date of grant, subject to the Reporting Person's continued service with the Issuer.

2. Adoption date of referenced 10b5-1(c) plan is: 03-12-2025

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.98 to $7.32, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

	/s/ Gordon Esplin as attorney-in-fact for Troy E. Wilson	06/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transactions did PBYI director Troy Edward Wilson report?

Troy Edward Wilson reported a grant and a sale. He received 27,000 Restricted Stock Units and sold 10,800 shares of Puma Biotechnology common stock in an open-market transaction, all detailed in the Form 4 insider trading report.

How many Puma Biotechnology (PBYI) shares did Troy Edward Wilson sell and at what price?

He sold 10,800 shares in the open market. The weighted average sale price was $7.1989 per share, based on multiple trades executed in a price range between $6.98 and $7.32, as disclosed in the filing footnotes.

What RSU award did PBYI grant to director Troy Edward Wilson?

Wilson received 27,000 Restricted Stock Units (RSUs). These RSUs vest in full on the earlier of the one-year anniversary of the grant date or the next annual shareholder meeting, contingent on his continued service with Puma Biotechnology.

How many Puma Biotechnology shares does Troy Edward Wilson own after these transactions?

After the transactions, Wilson holds 59,750 shares directly. He also has indirect ownership of 400 shares held for one child and 150 shares for another child, bringing his reported total visible holdings to 60,300 shares.

Was Troy Edward Wilson’s PBYI share sale under a Rule 10b5-1 plan?

Yes, the share sale was under a Rule 10b5-1(c) plan. A footnote states the trading plan’s adoption date as March 12, 2025, indicating the 10,800-share sale followed a pre-arranged schedule rather than discretionary timing.

When will Troy Edward Wilson’s Puma Biotechnology RSUs vest?

The RSUs vest on the earlier of two dates. They vest in full on the one-year anniversary of the grant date or on the date of the next annual shareholder meeting, assuming his continued service with Puma Biotechnology through that time.